One of the few places that will quote cagrilintide 5 mg at all, and the synthesis came back clean on an independent check.
JEEP — Guangzhou JEEP Biotechnology Co., Ltd.
Guangzhou, CN. The index holds 283 assay reports across 50 batches and 28 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where JEEP sells
Guangzhou JEEP Biotechnology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Guangzhou JEEP Biotechnology Co., Ltd.
- Short code in this index
- JEEP
- Also known as
- JEEP · JEEP Peptides · JEEP Bio
- Domain
- jeepbio.com →
- City
- Guangzhou
- Region
- Guangdong
- Country
- CN
- Established
- not stated
- First record in index
- 13 Feb 2024
- Most recent record
- 17 Oct 2026
Dispatch and warehouses
Where the supplier holds regional stock. Material assayed by the index is dispatched from these locations, not from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Across the 36 JEEP lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.85 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of JEEP batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 74% | 25 points | |
| Peptide content stated | 62% | 20 points | |
| Endotoxin stated | 32% | 15 points | |
| Named impurities rather than a total | 63% | 15 points |
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| BPC-157 | Tissue-repair | 43 | 99.41 | 99.15 | +0.26 | 98.0 | 100 |
| Semaglutide | Incretin | 39 | 99.13 | 98.87 | +0.26 | 97.0 | 100 |
| Tirzepatide | Incretin | 29 | 99.17 | 98.44 | +0.73 | 97.0 | 100 |
| TB-500 | Tissue-repair | 26 | 99.72 | 99.47 | +0.25 | 98.5 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 13 | 99.60 | 99.37 | +0.23 | 98.5 | 100 |
| CJC-1295 with DAC | Growth-hormone | 12 | 99.21 | 98.79 | +0.42 | 97.5 | 100 |
| N-Acetyl Semax Amide | Neuroactive | 12 | 99.93 | 99.26 | +0.67 | 98.5 | 100 |
| Liraglutide | Incretin | 12 | 99.48 | 99.02 | +0.46 | 97.5 | 100 |
| SS-31 (Elamipretide) | Metabolic | 11 | 99.39 | 99.42 | -0.03 | 98.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 10 | 99.44 | 99.31 | +0.13 | 98.5 | 100 |
| Retatrutide | Incretin | 9 | 98.00 | 98.41 | -0.41 | 96.5 | 100 |
| Leuprolide | Hypothalamic | 9 | 99.06 | 99.01 | +0.05 | 98.5 | 89 |
| ARA-290 | Tissue-repair | 8 | 99.02 | 99.45 | -0.44 | 98.0 | 100 |
| MOTS-c | Metabolic | 8 | 99.67 | 99.18 | +0.49 | 98.0 | 100 |
| Melanotan II | Melanocortin-receptor | 5 n=5 | 99.57 | 99.24 | +0.33 | 98.5 | 100 |
| L-Glutathione (reduced) | Short | 5 n=5 | 99.08 | 99.00 | +0.08 | 98.5 | 100 |
| Semax | Neuroactive | 5 n=5 | 99.09 | 99.17 | -0.08 | 98.5 | 100 |
| GHRP-2 | Growth-hormone | 5 n=5 | 99.41 | 99.22 | +0.19 | 99.0 | 80 |
| GHRP-6 | Growth-hormone | 5 n=5 | 99.57 | 99.65 | -0.08 | 99.0 | 100 |
| IGF-1 DES (1-3) | Growth-hormone | 3 n=3 | 99.75 | 98.53 | +1.22 | 95.0 | 100 |
| Hexarelin | Growth-hormone | 2 n=2 | n<3 | 98.72 | — | 99.0 | 100 |
| Cagrilintide | Incretin | 2 n=2 | n<3 | 98.59 | — | 96.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 2 n=2 | n<3 | 97.75 | — | 95.0 | 100 |
| 5-Amino-1MQ | Non-peptide | 2 n=2 | n<3 | 99.24 | — | 98.0 | 100 |
| Epitalon | Short | 2 n=2 | n<3 | 98.63 | — | 99.0 | 100 |
| KPV | Tissue-repair | 2 n=2 | n<3 | 99.21 | — | 99.0 | 100 |
| Thymulin | Tissue-repair | 1 n=1 | n<3 | 99.06 | — | 98.0 | 100 |
| Pinealon | Short | 1 n=1 | n<3 | 99.24 | — | 99.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 1 | 3 | 98.87 | 98.19–99.03 | 2 |
| 2024-Q2 | 2 | 7 | 99.43 | 99.14–99.72 | 5 |
| 2024-Q3 | 1 | 7 | 99.61 | 98.87–99.93 | 7 |
| 2024-Q4 | 7 | 51 | 99.08 | 97.39–99.93 | 44 |
| 2025-Q1 | 2 | 9 | 99.59 | 98.65–99.93 | 7 |
| 2025-Q2 | 5 | 37 | 99.44 | 98.38–99.93 | 23 |
| 2025-Q3 | 4 | 32 | 99.35 | 98.01–99.93 | 29 |
| 2025-Q4 | 10 | 47 | 99.74 | 97.64–99.93 | 19 |
| 2026-Q1 | 7 | 34 | 99.48 | 98.53–99.93 | 22 |
| 2026-Q2 | 7 | 34 | 99.25 | 98.38–99.88 | 22 |
| 2026-Q3 | 4 | 22 | 99.70 | 98.51–99.93 | 20 |
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 128 | 99.41 | +0.00 | 99.41 |
| PeptideMeter | 50 | 99.44 | -0.05 | 99.49 |
| Medutest | 42 | 99.63 | +0.08 | 99.55 |
| VendorInvestigate | 22 | 98.81 | -0.11 | 98.92 |
| Nordanalyt | 20 | 99.46 | +0.02 | 99.44 |
| Kestrel | 21 | 99.91 | +0.24 | 99.67 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
What this data does and does not show
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
Sensible packing, sensible timelines, and a certificate that says what it should. No notes.
Quoted 5 days, arrived in 5. Tracking updated at every hop from dispatch to door.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Reordered on the strength of the last one and got an identical result. Repeatability is the product.
Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.
Domestic dispatch from their stock in the United States. Straightforward, day 4, exactly as quoted.
Ordered on a Monday from their warehouse in Germany and it was here by day 2. That is the whole case for regional stock.
No customs paperwork, no import wait — it came from their stock in the United Kingdom and arrived day 2.
Submitted the MOTS-c 10 mg to Medutest blind, without telling them the source. 98.2% against a stated 97.8%. The number holds up when nobody knows whose vial it is.
Third order and it went the same way as the first two. Predictable in the way you want a supplier to be.
Ordered IGF-1 LR3 1 mg twice. Both vials reconstituted cleanly and both matched their certificates.
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
Queried the related-substances total on lot JEE-26-663; they came back with method, column and detection limit. That depth is rare.
Their warehouse in the United States had the KPV 10 mg in stock and it shipped the same afternoon. Tracking never left the country.
Solid on the semax 10 mg. Purity where it should be, transit 5 days, paperwork in order.
Reliable on the general catalogue lines. Purity figures cluster tightly and the certificates match the lots.
Consistent rather than flashy. Everything lands in the high nineties, and it lands there every time.
7 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
Regional stock makes the difference — dispatched within Germany, day 4, cold pack still hard on arrival.
Cold pack was still hard on arrival in Hamburg on day 3. My logger never went above 7°C across the whole run.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
Everything about the order was routine in the best sense — quoted 4 days, arrived in 4.
PeptideMeter has now seen 3 of their lots through me. Not one has come back outside spec.
Same lot documentation as the factory ships, but out of their warehouse in Canada, so it landed on day 4.
Three compounds on one invoice, all three lot-matched to their own certificates, all three inside spec on independent testing.
Most recent records
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041847 | TB-500 | JEEP-2602-V3434 | Nordanalyt | 2026-Q3 | 99.72 | 3.85 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041886 | Semaglutide | JEEP-2607-X3911 | Nordanalyt | 2026-Q3 | 99.19 | 4.03 | 96.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041882 | Semaglutide | JEEP-2607-X3911 | Nordanalyt | 2026-Q3 | 99.17 | 4.52 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041845 | TB-500 | JEEP-2602-V3434 | Janoshik | 2026-Q3 | 99.72 | 4.04 | 102.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041921 | TB-500 | JEEP-2605-M4874 | Janoshik | 2026-Q3 | 99.90 | 1.76 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041922 | TB-500 | JEEP-2605-M4874 | Janoshik | 2026-Q3 | 99.41 | 2.60 | 95.7 | Laboratory-retained | 2 | MARGINAL |
| AX-2026-041928 | TB-500 | JEEP-2605-M4874 | Janoshik | 2026-Q3 | 99.88 | 1.84 | 92.8 | Laboratory-retained | 2 | MARGINAL |
| AX-2026-041849 | TB-500 | JEEP-2602-V3434 | VendorInvestigate | 2026-Q3 | 99.73 | 3.60 | 88.6 | Buyer-sourced | 2 | MARGINAL |
| AX-2026-041926 | TB-500 | JEEP-2605-M4874 | Medutest | 2026-Q3 | 99.93 | 2.15 | 106.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041925 | TB-500 | JEEP-2605-M4874 | PeptideMeter | 2026-Q3 | 99.93 | 2.15 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041850 | TB-500 | JEEP-2602-V3434 | Medutest | 2026-Q3 | 99.93 | 3.44 | 99.1 | Supplier-supplied | 2 | FAIL |
| AX-2026-041885 | Semaglutide | JEEP-2607-X3911 | PeptideMeter | 2026-Q3 | 98.62 | 4.04 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041924 | TB-500 | JEEP-2605-M4874 | PeptideMeter | 2026-Q3 | 99.45 | 1.54 | — | Laboratory-retained | 2 | MARGINAL |
| AX-2026-041848 | TB-500 | JEEP-2602-V3434 | Janoshik | 2026-Q3 | 99.50 | 3.15 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041892 | Hexarelin | JEEP-2608-Y4367 | Janoshik | 2026-Q3 | 99.55 | 3.61 | 98.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041923 | TB-500 | JEEP-2605-M4874 | PeptideMeter | 2026-Q3 | 99.59 | 1.63 | 104.1 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041884 | Semaglutide | JEEP-2607-X3911 | Medutest | 2026-Q3 | 99.69 | 3.35 | 100.4 | Supplier-supplied | 1 | FAIL |
| AX-2026-041846 | TB-500 | JEEP-2602-V3434 | Janoshik | 2026-Q3 | 99.93 | 3.30 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041881 | Semaglutide | JEEP-2607-X3911 | Kestrel | 2026-Q3 | 99.93 | 3.74 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041883 | Semaglutide | JEEP-2607-X3911 | Janoshik | 2026-Q3 | 98.51 | 4.11 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041927 | TB-500 | JEEP-2605-M4874 | Nordanalyt | 2026-Q3 | 99.76 | 1.75 | 105.3 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041864 | PT-141 (Bremelanotide) | JEEP-2601-K3015 | Janoshik | 2026-Q2 | 99.35 | 3.99 | 92.2 | Supplier-supplied | 0 | PASS |
| AX-2026-041893 | Hexarelin | JEEP-2608-Y4367 | PeptideMeter | 2026-Q3 | 99.44 | 3.58 | 103.2 | Supplier-supplied | 0 | PASS |
| AX-2026-041860 | PT-141 (Bremelanotide) | JEEP-2601-K3015 | PeptideMeter | 2026-Q2 | 99.75 | 4.23 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041887 | Melanotan II | JEEP-2604-R3923 | Janoshik | 2026-Q2 | 99.56 | 5.05 | 95.2 | Supplier-supplied | 0 | PASS |